Developing next-generation T-Regulatory (Tregs) cell therapies and mRNA immunotherapies for Type 1 Diabetes, MS, ALS, and autoimmune/inflammatory diseases with collaborative partners.
ABOUT US
At Immuthera, the key to treating autoimmune diseases lies within the immune system itself. By harnessing and enhancing natural Treg cells, we develop therapies that don’t just suppress symptoms—they restore balance. From our clinically proven PTG-007 platform to cutting-edge CAR-Tregs and other novel modalities, we will build a future where autoimmune and neuroinflammatory diseases can be defeated.
OUR SCIENCE
T regulatory cells (Tregs) play a critical role in maintaining immune homeostasis. Immuthera is developing therapies that utilize Tregs to control and suppress harmful immune reactions in autoimmune diseases. Our PTG-007 platform serves as the foundation for developing a range of engineered Treg modalities.
THERAPEUTIC DEVELOPMENT
PTG-007+ / rituximab
PTG-007 + commonly used MS drug
CAR-TREGS
PARTNERS
We are actively seeking partners for existing programs and to develop new therapeutic programs.
Immuthera is a wholly owned subsidiary of PolTREG S.A. based in the United States. Immuthera works closely with PolTREG to leverage cutting edge research for the development of next generation Tregulatory and mRNA-based immunotherapies in the US. Immuthera will also work with PolTREG to expand ongoing and future clinical studies with core assets into the US.
Immuthera will leverage PolTREG’s clinical stage and pipeline assets into the US Market, the largest global market for autoimmune and neuroinflammatory disease. Immuthera will work with the US FDA, US Institutions, and US companies to advance these assets to realize their full commercial potential.
Immuthera and PolTREG have an exclusive deal to develop multiple multi-edited and Allogeneic CAR-Tregs for Autoimmune disease and Neuroinflammation. These Multi-edited and Allogeneic CAR-Tregs are engineered into PolTREG’s clinically validated and safe PTG-007 “backbone”. The specific edits that are being developed were discovered in patients who responded well to therapy and had functionally superior Tregs to controls or non-responders.
Antion’s proprietary, multiplex, and modular platform can simultaenously add, delete, or “tune down” the expression of multiple genes in a single construct. The ability to tune down expression of specific genes has been shown by Antion to be superior than completely knocking out function.
NEWS & UPDATES
CONTACT US